CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Company’s product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.
企業コードCDNA
会社名CareDx Inc
上場日Jul 17, 2014
最高経営責任者「CEO」Mr. John W. Hanna
従業員数644
証券種類Ordinary Share
決算期末Jul 17
本社所在地8000 Marina Blvd
都市BRISBANE
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号94005
電話番号14152872300
ウェブサイトhttps://www.caredx.com/
企業コードCDNA
上場日Jul 17, 2014
最高経営責任者「CEO」Mr. John W. Hanna
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし